ClinicalTrials.gg
CompletedNCT03998696HNCUpdated Oct 16, 2026Results posted

An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.

A Phase 2 interventional study of Cisplatin 40 mg/m2 and Cisplatin 100 mg/m2 in Head and Neck Squamous Cell Carcinoma, sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Completed at 1 site in Bangladesh. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Phase 2, Interventional, and Treatment

How we know

Updated Oct 16, 2026Results postedStudy documents posted+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck — 19 open to participants now, 31 under way, 5 of them phase 3. Cisplatin · Squamous Cell Carcinoma of Head and Neck.

Enrollment
45th of 107
60 · median 47
Started
2024
with 3 others
Phase 2
70 of 115
18 open now
Registered
91st of 115
by date

Among the 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck, this one is the 45th largest by enrollment of the 107 interventional ones that give a count, is one of 4 that started in 2024, is one of 70 in phase 2, and was the 91st registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

19 of the 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

The aim of this study is to compare treatment responses and toxicities of concurrent chemo-radiation with weekly and three weekly Cisplatin in locally advanced Head \& Neck Cancer. Half of the participants received Cisplatin (40 mg/m2) weekly with radiotherapy, while the other half received Cisplatin (100 mg/m2) thrice weekly with radiotherapy. Radiotherapy continued five days per week for six and half weeks.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma

Keywords

  • Locally advanced
  • Head and Neck Cancer
  • Concurrent
  • Weekly Cisplatin
  • Three weekly Cisplatin
  • Radiotherapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proved, previously untreated, Squamous cell carcinoma of head \& neck
  • Stages III to IVB

Exclusion criteria

Exclusion Criteria:

  • Patients with history of prior chemotherapy or radiotherapy to the head and neck region.
  • Initial surgery (excluding diagnostic ) of the primary site.
  • Patients with synchronous primaries.
  • Those who are not willing to be included in the study.
  • Pregnant or lactating woman.
  • Serious medical illness
  • Prisoners.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Arm A

    Weekly Cisplatin

    Drug: Cisplatin 40 mg/m2

  • Experimental
    Arm B

    Three weekly Cisplatin

    Drug: Cisplatin 100 mg/m2

Interventions

  • DrugCisplatin 40 mg/m2

    Drug page: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cisplatin 40 mg /m2 intravenous infusion delivered concurrently with radiotherapy on a weekly basis.

  • DrugCisplatin 100 mg/m2

    Drug page: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cisplatin 100 mg/m2 intravenous infusion delivered on a three weekly basis on days 1, 22 and 43 delivered concurrently with radiotherapy.

06

What researchers measure

Primary outcomes

  1. Loco-regional Tumor Control After Completion of Treatment

    Response Evaluation Criteria in Solid Tumors was used to measure outcome: 1. Complete response (CR): Disappearance of all target lesions. 2. Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions. 3. Progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions. 4. Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: 6 months

  2. Distribution of the Patients by Oral Mucositis

    Radiation Therapy Oncology Group (RTOG) toxicity criteria was used to measure toxicities related to oral mucosa. Grade I: Irritation / may experience mild pain not requiring analgesic. Grade II: Patchy mucositis that may produce an inflammatory serosanguinous discharge / may experience moderate pain requiring analgesia. Grade III: Confluent fibrinous mucositis / may include severe pain requiring narcotic. Grade IV: Ulceration, hemorrhage or necrosis.

    Time frame: 8 months

07

Results

Posted Oct 16, 2026
Limitations and caveats
1. Non-randomized study - unable to prevent selection bias. 2. Short study period - late toxicities and survival data could not be measured. 3. Sample size - great limitation to get an accurate clinical outcome.

Participant flow

Participant flow — Overall Study
MilestoneArm AArm B
Started3030
Completed3030
Not completed00

Outcome measures

PrimaryLoco-regional Tumor Control After Completion of Treatment

Response Evaluation Criteria in Solid Tumors was used to measure outcome: 1. Complete response (CR): Disappearance of all target lesions. 2. Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions. 3. Progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions. 4. Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
6 months
Reported as:
Count of participants · Participants
Loco-regional Tumor Control After Completion of Treatment
ParticipantsArm AArm B
Complete response1923
Partial response85
Progressive disease32
Statistical analysis
  • Arm A vs Arm B · Fisher Exact · p = 0.534
PrimaryDistribution of the Patients by Oral Mucositis

Radiation Therapy Oncology Group (RTOG) toxicity criteria was used to measure toxicities related to oral mucosa. Grade I: Irritation / may experience mild pain not requiring analgesic. Grade II: Patchy mucositis that may produce an inflammatory serosanguinous discharge / may experience moderate pain requiring analgesia. Grade III: Confluent fibrinous mucositis / may include severe pain requiring narcotic. Grade IV: Ulceration, hemorrhage or necrosis.

Time frame:
8 months
Reported as:
Count of participants · Participants
Distribution of the Patients by Oral Mucositis
ParticipantsArm AArm B
Grade I oral mucositis416
Grade II oral mucositis1810
Grade III oral mucositis84
Statistical analysis
  • Arm A vs Arm B · Fisher Exact · p = 0.004

Adverse events

Collected over 8 months. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A0/30 (0%)0/30 (0%)30/30 (100%)
Arm B0/30 (0%)0/30 (0%)30/30 (100%)
Most frequent other events
Most frequent other events
EventArm AArm B
VomitingGeneral disorders22/3020/30
AnemiaBlood and lymphatic system disorders8/3010/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm AArm BTotal
<=18 years000
Between 18 and 65 years242650
>=65 years6410
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BTotal
Female10919
Male202141
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Arm AArm BTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Arm AArm BTotal
Bangladesh303060
Occupational status
Occupational status(Participants)Arm AArm BTotal
Farmers101222
Service holders549
Businessmen4610
Housewives7512
Unemployed437
Smoking habit
Smoking habit(Participants)Arm AArm BTotal
Yes232548
No7512
Primary site of tumor
Primary site of tumor(Participants)Arm AArm BTotal
Oral cavity9817
Larynx6915
Oropharynx8614
Hypopharynx459
Others325
Stage of disease
Stage of disease(Participants)Arm AArm BTotal
Stage III111324
Stage IVA101121
Stage IVB9615
08

Study locations

1 site
  • Bangladesh Medical University
    Dhaka, 1000, Bangladesh
09

References and documents

Publications

  • Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan 1;21(1):92-8. doi: 10.1200/JCO.2003.01.008. PubMed 12506176 ↗
  • Geeta SN, Padmanabhan TK, Samuel J, Pavithran K, Iyer S, Kuriakose MA. Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers. J Cancer Res Ther. 2006 Jul-Sep;2(3):100-4. doi: 10.4103/0973-1482.27584. PubMed 17998687 ↗
  • Guan J, Zhang Y, Li Q, Zhang Y, Li L, Chen M, Xiao N, Chen L. A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC). Oncotarget. 2016 Oct 25;7(43):70185-70193. doi: 10.18632/oncotarget.11824. PubMed 27602493 ↗
  • Ho KF, Swindell R, Brammer CV. Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol. 2008;47(8):1513-8. doi: 10.1080/02841860701846160. PubMed 18607863 ↗
  • Jacinto JK, Co J, Mejia MB, Regala EE. The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis. Br J Radiol. 2017 Nov;90(1079):20170442. doi: 10.1259/bjr.20170442. PubMed 29053029 ↗
  • Lee JY, Sun JM, Oh DR, Lim SH, Goo J, Lee SH, Kim SB, Park KU, Kim HK, Hong DS, Kim JS, Kim SG, Yi SY, Yun HJ, Hyun MS, Kim HJ, Jung SH, Park K, Ahn YC, Ahn MJ. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). Radiother Oncol. 2016 Feb;118(2):244-50. doi: 10.1016/j.radonc.2015.11.030. Epub 2015 Dec 17. PubMed 26705681 ↗
  • Tsan DL, Lin CY, Kang CJ, Huang SF, Fan KH, Liao CT, Chen IH, Lee LY, Wang HM, Chang JT. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol. 2012 Dec 18;7:215. doi: 10.1186/1748-717X-7-215. PubMed 23245290 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

Access criteria: To request an electronic copy send email to dr.iurahim@gmail.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Dec 2024, 11 months.

Results were first posted in Oct 2026, 1 year 9 months after primary completion.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's 11 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Jul 2017 → Jan 2024, primary completion Jun 2018 → Dec 2024 and completion Dec 2018 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2019
First posted
Jun 26, 2019
StartActual
Jan 1, 2024was Jul 2017
Primary completionActual
Dec 31, 2024was Jun 2018
CompletionActual
Jun 30, 2025was Dec 2018
Results first posted
Oct 16, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 16, 2026
Sites
1 site added, 1 site removed
Show site
  • Bangladesh Medical University · Dhaka, Bangladesh
Show 1 removed
  • Bangabandhu Sheikh Mujib Medical University · Dhaka, Bangladesh
Oct 16, 2026
Start date
Jul 1, 2017→Jan 1, 2024
Oct 16, 2026
Primary completion
Jun 30, 2018→Dec 31, 2024
Oct 16, 2026
Study completion
Dec 31, 2018→Jun 30, 2025
Oct 16, 2026
Interventions
Arms added: Arm A·Arm B; arms removed: Weekly Cisplatin·Three weekly Cisplatin
Oct 16, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedLoco-regional tumor control after completionTumor Control After Completion of treatmentTreatmentTime frame: 6 months
  • ChangedBefore Treatment related toxicities during and after treatmentNow Distribution of the Patients by Oral MucositisTime frame: 8 months
Oct 16, 2026
Documents
Design
Phase 4→Phase 2
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Bangladesh Medical University · Dhaka, Bangladesh
    Show 1 removed
    • Bangabandhu Sheikh Mujib Medical University · Dhaka, Bangladesh
    Start date Jul 1, 2017→Jan 1, 2024
    Primary completion Jun 30, 2018→Dec 31, 2024
    Study completion Dec 31, 2018→Jun 30, 2025
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedLoco-regional tumor control after completionTumor Control After Completion of treatmentTreatmentTime frame: 6 months
    • ChangedBefore Treatment related toxicities during and after treatmentNow Distribution of the Patients by Oral MucositisTime frame: 8 months
    Interventions Arms added: Arm A·Arm B; arms removed: Weekly Cisplatin·Three weekly Cisplatin
    Design Phase 4→Phase 2
    + 6 other changes: identifiers, verification date, responsible party, contact details, registry notes and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03998696
Responsible party
Dr. Ishtiaq-Ur-Rahim (Principal Investigator, Bangladesh Medical University) — Principal investigator
First posted
Jun 26, 2019
Start date
Jan 1, 2024
Primary completion
Dec 31, 2024
Completion
Jun 30, 2025
Results posted
Oct 16, 2026
Last update
Oct 16, 2026

Study contacts

Sarwar Alam, MBBS, Mphil
study chair · Bangladesh Medical University, Dhaka, Bangladesh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cisplatin

Start the discussion